DE69028535D1 - Herstellung des vaskulären endothelialen zellwachstumsfaktors - Google Patents

Herstellung des vaskulären endothelialen zellwachstumsfaktors

Info

Publication number
DE69028535D1
DE69028535D1 DE69028535T DE69028535T DE69028535D1 DE 69028535 D1 DE69028535 D1 DE 69028535D1 DE 69028535 T DE69028535 T DE 69028535T DE 69028535 T DE69028535 T DE 69028535T DE 69028535 D1 DE69028535 D1 DE 69028535D1
Authority
DE
Germany
Prior art keywords
growth factor
cell growth
vascular endothelial
endothelial cell
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69028535T
Other languages
English (en)
Other versions
DE69028535T2 (de
Inventor
Edmund Tischer
Judith Abraham
John Fiddes
Richard Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios Nova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Nova Inc filed Critical Scios Nova Inc
Publication of DE69028535D1 publication Critical patent/DE69028535D1/de
Application granted granted Critical
Publication of DE69028535T2 publication Critical patent/DE69028535T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
DE69028535T 1989-07-27 1990-07-27 Herstellung des vaskulären endothelialen zellwachstumsfaktors Expired - Lifetime DE69028535T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38754589A 1989-07-27 1989-07-27
US07/450,883 US5194596A (en) 1989-07-27 1989-12-14 Production of vascular endothelial cell growth factor
PCT/US1990/004227 WO1991002058A1 (en) 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor

Publications (2)

Publication Number Publication Date
DE69028535D1 true DE69028535D1 (de) 1996-10-17
DE69028535T2 DE69028535T2 (de) 1997-04-10

Family

ID=27011922

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69028535T Expired - Lifetime DE69028535T2 (de) 1989-07-27 1990-07-27 Herstellung des vaskulären endothelialen zellwachstumsfaktors

Country Status (10)

Country Link
US (1) US5194596A (de)
EP (1) EP0484401B1 (de)
JP (4) JP3523645B2 (de)
AT (1) ATE142693T1 (de)
AU (1) AU6079890A (de)
CA (1) CA2063810C (de)
DE (1) DE69028535T2 (de)
DK (1) DK0484401T3 (de)
ES (1) ES2094159T3 (de)
WO (1) WO1991002058A1 (de)

Families Citing this family (434)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6899882B1 (en) 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
DK0464155T3 (da) * 1989-03-24 1997-11-17 Univ California Endotelcellevækstfaktor, isolering og ekspression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (de) * 1989-05-24 1995-12-20 Merck & Co. Inc. Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2064331C (en) 1991-03-28 2003-02-18 Marvin L. Bayne Vascular endothelial cell growth factor c subunit
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5514779A (en) * 1991-06-07 1996-05-07 Zeneca Limited Biocidal proteins from plants
AU2861692A (en) * 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
JP3504263B2 (ja) * 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
AU5125693A (en) * 1992-09-03 1994-03-29 Regents Of The University Of California, The Dorsal tissue affecting factor and compositions
CA2145985C (en) * 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
AU6778794A (en) * 1993-04-29 1994-11-21 Washington University Use of platelet-derived growth factor to improve collateral circulation
EP1493812A3 (de) * 1993-06-29 2006-02-08 Chiron Corporation Verkürzter Keratinozyten-Wachstumsfaktor (KGF) mit erhöhter biologischer Aktivität
WO1995006131A1 (en) * 1993-08-23 1995-03-02 Monash University A method for the assay, prophylaxis and/or treatment of human disease conditions
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
DE59410132D1 (de) * 1993-12-24 2002-07-11 Forssmann Wolf Georg Humanes zirkulierendes cytokin cc-1
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
ES2249762T3 (es) * 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6150092A (en) * 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
CA2212573A1 (en) * 1995-02-09 1996-08-15 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Nucleotide and deduced amino acid sequences of tumor gene int6
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) * 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7160991B1 (en) * 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
ATE252600T1 (de) * 1995-03-02 2003-11-15 Amrad Operations Pty Ltd Ein neuartiger wachstumfaktor und eine genetische sequenz die für diesen kodiert
JPH11503012A (ja) * 1995-03-30 1999-03-23 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトｇタンパク質結合レセプター
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US7427492B1 (en) * 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) * 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US20020150578A1 (en) * 1995-06-05 2002-10-17 Human Genome Sciences, Inc. Human prostatic specific reductase
US20020026037A1 (en) * 1995-06-06 2002-02-28 Jing-Shan Hu Vascular endothelial growth factor 3 antibodies
US6013483A (en) * 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
AU6777196A (en) * 1995-08-15 1997-03-12 Connective Therapeutics Inc. Method of promoting angiogenesis
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
US6329169B1 (en) * 1995-09-29 2001-12-11 Human Genome Sciences, Inc. Nucleic acid molecules encoding cytostatin II
AU7142996A (en) * 1995-09-29 1997-04-28 Universita' Degli Studi Di Siena Regulated genes and uses thereof
DE69629826T2 (de) * 1995-10-23 2004-07-01 Children's Medical Center Corp., Boston Therapeutische antiangiogenische zusammensetzungen und verfahren
US7393943B1 (en) * 1995-12-08 2008-07-01 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic cytokine I
US7888466B2 (en) * 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7084252B1 (en) * 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
ATE364629T1 (de) * 1996-01-22 2007-07-15 Curis Inc Methoden zur herstellung von op-1 morphogen analoge
WO1997029701A1 (en) 1996-02-15 1997-08-21 Biosense Inc. Catheter based surgery
US6713061B1 (en) * 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6410268B1 (en) 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
US6443974B1 (en) * 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
DK0956339T3 (da) * 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
US20030129643A1 (en) * 1996-08-23 2003-07-10 Human Genome Sciences, Inc. T1 receptor-like ligand I
EP0860447B1 (de) * 1996-08-27 2007-07-18 Kyowa Hakko Kogyo Co., Ltd. Hämatopoetischer stammzellenwachstumsfaktor (scgf)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
JP2001501471A (ja) * 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド 血管新生の阻害のための遺伝子治療
US20070299005A1 (en) * 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US6998418B1 (en) 1996-11-05 2006-02-14 Gp Medical, Inc. Acellular biological material chemically treated with genipin
US20060171907A1 (en) * 1996-11-21 2006-08-03 The Procter & Gamble Company Oral care compositions providing enhanced whitening and stain prevention
EP2003203A1 (de) * 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
KR20000070174A (ko) * 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
US7285267B2 (en) * 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US20040013664A1 (en) * 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
WO1998031800A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Human proteins
US20020155538A1 (en) * 1997-01-23 2002-10-24 Incyte Pharmaceuticals, Inc. Novel endothelial growth factor
AU6267098A (en) * 1997-02-05 1998-08-25 Regents Of The University Of California, The Morphogenic proteins
WO1998035039A1 (en) * 1997-02-06 1998-08-13 Human Genome Sciences, Inc. Dendritic cell-derived growth factor
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6395707B1 (en) * 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6951924B2 (en) * 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
ATE296117T1 (de) 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US7968689B2 (en) * 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998046249A1 (en) * 1997-04-15 1998-10-22 Radix Organization, Inc. Method of treating gastrointestinal ulcers and compositions therefor
US7205381B2 (en) * 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
US20030166065A1 (en) * 1997-04-24 2003-09-04 Human Genome Sciences, Inc. Novel integrin ligand ITGL-TSP
US7220557B2 (en) 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
EP0979282A1 (de) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rattenchemonikin st38.2
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6031155A (en) * 1997-06-05 2000-02-29 Cameron-Mills; Verena Arabinoxylan degradation
US20060223077A1 (en) * 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US5891674A (en) * 1997-06-19 1999-04-06 Incyte Pharmaceuticals, Inc. Insulin receptor tyrosine kinase substrate
EP0996725A1 (de) * 1997-06-27 2000-05-03 Human Genome Sciences, Inc. Menschliches nk-3 verwandtes prostata-spezifiches gen -1
US6635480B1 (en) * 1997-07-31 2003-10-21 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
WO1999006444A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University Of School Of Medicine GROWTH DIFFERENTIATION FACTOR, Lefty-1
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
US20020112251A1 (en) * 1997-08-04 2002-08-15 Mccarthy Sean A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US20030082540A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE442385T1 (de) 1997-09-17 2009-09-15 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
CA2303762A1 (en) * 1997-09-22 1999-04-01 Toshio Miyata Megsin protein
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
US6808890B2 (en) * 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
EP1029045A2 (de) * 1997-11-13 2000-08-23 Genset VERLÄNGERTE cDNAs, DIE FÜR SEKRETIERTE PROTIEINE KODIEREN
US20060009633A9 (en) * 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
US20060286639A1 (en) * 1997-11-13 2006-12-21 Serono Genetics Institute S.A. Complementary DNAs encoding proteins with signal peptides
JP2002504308A (ja) 1997-11-22 2002-02-12 ハイセック インコーポレイテッド 胎児肝−脾臓のｃＤＮＡライブラリーから得られた新規ＥＧＦモチーフタンパク質
US20020132981A1 (en) * 1997-12-03 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6309879B1 (en) * 1997-12-08 2001-10-30 Curis, Inc. Human patched genes and proteins, and uses related thereto
US6303770B1 (en) * 1997-12-10 2001-10-16 Zymogenetics, Inc. Nucleic acids encoding mammalian alpha helical protein-1
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6703485B2 (en) * 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
KR100628697B1 (ko) * 1997-12-24 2006-09-28 루드빅 인스티튜트 포 캔서 리서치 맥관 내피 성장인자 ｄ를 발현하는 발현 벡터와 셀라인,및 흑색종을 치료하는 방법
JPH11187884A (ja) * 1997-12-26 1999-07-13 Hsp Kenkyusho:Kk 熱ショック転写因子結合蛋白質
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2451199A (en) * 1998-01-07 1999-07-26 Human Genome Sciences, Inc. 36 human secreted proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7722671B1 (en) 1998-01-27 2010-05-25 St. Jude Medical, Inc. Medical devices with associated growth factors
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US6309370B1 (en) 1998-02-05 2001-10-30 Biosense, Inc. Intracardiac drug delivery
AU767662B2 (en) 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
US6706869B1 (en) * 1998-02-11 2004-03-16 Wyeth Map kinase phosphatases and polynucleotides encoding them
US6395890B1 (en) * 1998-02-20 2002-05-28 Zymogenetics, Inc. Nucleic acids encoding connective tissue growth factor homologs
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20050026248A1 (en) * 1998-03-26 2005-02-03 Hsueh Aaron J.W. Novel mammalian G-protein coupled receptors having extracellular leucine rich repeat regions
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
US6573095B1 (en) * 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
EP1077259A4 (de) * 1998-05-14 2005-04-20 Ono Pharmaceutical Co Neue polypeptide, dafür kodierende cdnas und deren verwendung
US7193045B2 (en) * 1998-05-15 2007-03-20 Genetech, Inc. Polypeptides that induce cell proliferation
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
WO1999062927A1 (en) * 1998-06-05 1999-12-09 Human Genome Sciences, Inc. Connective tissue growth factor-4
US20070020724A1 (en) 1998-06-16 2007-01-25 Ruben Steven M 94 human secreted proteins
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
TR200100074T2 (tr) * 1998-07-14 2001-11-21 Janssen Pharmaceutica N.V. Nevrotrofik büyüme faktörü
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
US20050048612A1 (en) * 1998-07-28 2005-03-03 Incyte Corporation Human epidermal proteins HEP1-1 to HEP1-6
US6706951B1 (en) * 1998-08-17 2004-03-16 Pioneer Hi-Bred International, Inc. Maize nucleic acid encoding a GDP-mannose pyrophosphorylase
WO2000011199A1 (en) * 1998-08-20 2000-03-02 Pioneer Hi-Bred International, Inc. COMPOSITIONS AND METHODS FOR ALTERING AN ACETYL-CoA METABOLIC PATHWAY OF A PLANT
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
AU5801099A (en) * 1998-09-02 2000-03-21 Millennium Pharmaceuticals, Inc. 14926 receptor, a novel g-protein coupled receptor
EP1417971A3 (de) * 1998-09-09 2004-06-30 Scios Inc. Verwendung eines angiogenen Faktors zur Behandlung von mikrovaskulären Angiopathien
AU6028599A (en) 1998-09-09 2000-03-27 Scios Inc. Methods of treating hypertension and compositions for use therein
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1114155A2 (de) * 1998-09-17 2001-07-11 Incyte Pharmaceuticals, Inc. Menschliche gpcr proteine
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
WO2000018923A2 (en) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Slgp protein and nucleic acid molecule and uses therefor
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP2002530058A (ja) * 1998-11-12 2002-09-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３１個のヒト分泌タンパク質
US6375680B1 (en) 1998-12-01 2002-04-23 St. Jude Medical, Inc. Substrates for forming synthetic tissues
EP1140970A4 (de) * 1998-12-17 2003-10-22 Human Genome Sciences Inc 47 menschliche sekretierte proteine
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2000189171A (ja) * 1998-12-25 2000-07-11 Banyu Pharmaceut Co Ltd 新規なグアノシン三リン酸（ｇｔｐ）結合タンパク質共役型のレセプタ―タンパク質
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2856400A (en) * 1999-01-25 2000-08-07 University Of Florida Materials and methods for producing geminivirus resistant plants
AU3590000A (en) * 1999-02-02 2000-08-25 Trustees Of Columbia University In The City Of New York, The Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
JP2002540763A (ja) * 1999-02-10 2002-12-03 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３３個のヒト分泌タンパク質
DE19906096A1 (de) * 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
US6392126B1 (en) * 1999-02-25 2002-05-21 Pioneer Hi-Bred International, Inc. Adenosine deaminase homologues and uses thereof
US7083793B2 (en) * 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6406907B1 (en) * 1999-02-26 2002-06-18 Iowa State University Research Foundation Bovine tumor necrosis factor receptor-1 and methods of use
WO2000052178A1 (en) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
IL128852A0 (en) * 1999-03-05 2000-01-31 Compugen Ltd Novel nucleic acid and amino acid sequences
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US6689866B1 (en) * 1999-03-09 2004-02-10 Curagen Corporation Polynucleotides and proteins encoded thereby
US8410248B2 (en) * 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US8133734B2 (en) * 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
US6965012B1 (en) * 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
ES2421720T3 (es) * 1999-04-12 2013-09-05 Genentech Inc Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
WO2000064261A1 (en) * 1999-04-26 2000-11-02 Ludwig Institute For Cancer Research Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1179590A4 (de) * 1999-04-30 2002-09-18 Kurokawa Kiyoshi Protein meg-3
US6475987B1 (en) * 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
EP1183352A1 (de) * 1999-05-20 2002-03-06 Scios Inc. Varianten vom vaskuläre endothelzellen wachstumsfaktor (vegf)
AU5026100A (en) * 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor dimers
CA2382774A1 (en) * 1999-05-25 2000-11-30 Human Genome Sciences, Inc. Meth1 and meth2 polynucleotides and polypeptides
US20030207793A1 (en) * 1999-05-26 2003-11-06 Conklin Darrell C. Secreted alpha-helical protein - 32
JP2003501072A (ja) * 1999-06-07 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２６個のヒト分泌タンパク質
US6781028B1 (en) * 1999-06-14 2004-08-24 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
US20030153050A1 (en) * 1999-06-28 2003-08-14 Conklin Darrell C. Helical polypeptide zalpha29
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
US6951738B2 (en) * 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
ATE449174T1 (de) * 1999-07-23 2009-12-15 Kenji Kangawa Neue peptide
WO2001010891A2 (en) * 1999-08-05 2001-02-15 Research Corporation Technologies, Inc. Il-16 antagonists
US20030134788A1 (en) * 1999-08-12 2003-07-17 Baker Kevin P. Human tumor necrosis factor receptor TR16
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
KR20050004240A (ko) * 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
US20030120037A1 (en) * 1999-09-22 2003-06-26 Ji Ming Wang Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
USRE39849E1 (en) 1999-10-12 2007-09-18 Chemocentryx, Inc. Methods for identifying modulators of CCX CKR activity
ATE402953T1 (de) * 1999-10-18 2008-08-15 Lexicon Pharmaceuticals Inc Menschliches chordin und polynukleotiden die dafür kodieren
US7459308B2 (en) * 1999-10-21 2008-12-02 Arbor Vita Corporation Nucleic acid molecule encoding a CLASP-2 transmembrane protein
US6726718B1 (en) 1999-12-13 2004-04-27 St. Jude Medical, Inc. Medical articles prepared for cell adhesion
US7029857B1 (en) * 1999-12-17 2006-04-18 H. Lundbeck A/S Processes for obtaining compounds employing SNORF72 receptors
JP2001211886A (ja) * 2000-02-07 2001-08-07 Japan Science & Technology Corp Ｌ−体及びｄ−体アミノ酸を輸送するナトリウム非依存性小型中性アミノ酸トランスポーター及びその遺伝子
CA2399387C (en) * 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US20030165891A1 (en) * 2000-02-29 2003-09-04 Millennium Pharmaceuticals, Inc. Novel TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9 alpha2delta-4, 54414, and 53763 molecules and uses therefor
AU2001245428B2 (en) * 2000-03-03 2006-04-27 University Of Utah Research Foundation Mass1 gene, a target for anticonvulsant drug development
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US20030119739A1 (en) * 2000-03-29 2003-06-26 Beth Israel Deaconess Medical Center Anti-angiogenic and anti-tumor properties of Vascostatin and other nidogen domains
US7070946B2 (en) * 2000-05-23 2006-07-04 Tanabe Seiyaku Co., Ltd. Bone metabolism related protein and gene thereof
NZ523157A (en) * 2000-05-31 2004-08-27 Ortho Mcneil Pharm Inc DNAs encoding mammalian histamine receptor of the H4 subtype
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
CA2413454A1 (en) * 2000-06-21 2001-12-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung A g-protein coupled receptor
NZ518077A (en) * 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
WO2002012334A2 (en) * 2000-08-07 2002-02-14 Zymogenetics, Inc. Snake venom polypeptide zsnk1
AU8881201A (en) * 2000-09-05 2002-03-22 Amgen Inc Tnf receptor-like molecules and uses thereof
CA2425833A1 (en) * 2000-10-13 2002-04-18 Hyseq, Inc. Egf motif protein, egfl6 materials and methods
US6489456B1 (en) * 2000-10-27 2002-12-03 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
GB0028971D0 (en) * 2000-11-28 2001-01-10 Inpharmatica Ltd Novel proteins
JP2004537260A (ja) * 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質による血管新生の調節
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20030180309A1 (en) * 2001-01-08 2003-09-25 Baum Peter R. Human B7 polypeptides
US20030186904A1 (en) * 2001-01-08 2003-10-02 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
AU2002258394A1 (en) * 2001-02-07 2002-09-12 Bristol-Myers Squibb Company Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
JP2004521128A (ja) * 2001-02-23 2004-07-15 ワイス Ｂｍｐによるヒト骨髄由来ｃｄ１０５＋細胞の軟骨形成能
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7741049B2 (en) * 2001-03-15 2010-06-22 Sumitomo Chemical Company, Limited Analysis of agonist-activity and antagonist-activity to cytokinin receptor
US6962971B2 (en) * 2001-03-16 2005-11-08 The Regents Of The University Of California Chemokines and methods for inducing the differentiation of fibroblasts to myofibroblasts
JP2004525930A (ja) * 2001-03-23 2004-08-26 バイオファーム・ゲゼルシャフト・ツア・バイオテクノロジシェン・エントヴィックルング・フォン・ファーマカ・ミット・ベシュレンクテル・ハフツング 皮膚関連疾患の治療及び診断のためのＴＧＦ−βスーパーファミリーのサイトカインの使用
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
EP1573022B1 (de) * 2001-04-10 2011-06-08 Agensys, Inc. Nukleinsäure und dieser entsprechendes, 184p1e2 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
DE60236646D1 (de) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US20030176674A1 (en) * 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
US20030086872A1 (en) * 2001-08-15 2003-05-08 Jean-Philippe Girard SUT-2 and SUT-3 genes, proteins and assays for inhibitors of lymphocyte adhesion
AU2002326742B2 (en) * 2001-08-21 2007-05-31 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
WO2003018752A2 (en) * 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
JPWO2003033727A1 (ja) * 2001-10-12 2005-02-03 山之内製薬株式会社 細胞死抑制剤スクリーニング法
JP2006504391A (ja) * 2001-10-17 2006-02-09 ザイモジェネティクス，インコーポレイティド 分泌されたタンパク質ｚｔｎｆ９
US7371258B2 (en) * 2001-10-26 2008-05-13 St. Jude Medical, Inc. Valved prosthesis with porous substrate
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
WO2003046147A2 (en) * 2001-11-26 2003-06-05 Bristol-Myers Squibb Company Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
US20030104496A1 (en) * 2001-11-30 2003-06-05 Cytokinetics, Inc. Novel motor protein of P. falciparum and methods for its use
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
CA2472927A1 (en) * 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
US20040162237A1 (en) * 2002-01-15 2004-08-19 Fox Niles Wayne Use of lp82 to treat body weight disorders
KR20030062789A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｓｉｍ2-ｂｔｍ 및 이것을포함하는 생명공학제품
KR20030062788A (ko) 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
EP1578921A4 (de) * 2002-01-23 2007-05-30 Univ Texas Tech Migrationsinduzierendes säugergen sowie verfahren zum nachweis und zur hemmung migrierender tumorzellen
WO2003064469A2 (en) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Regulation of human hematopoietin receptor-like protein
GB0202906D0 (en) * 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
AU2003214171A1 (en) * 2002-03-12 2003-09-29 Harold Brem Method for treating diabetic ulcers
AU2003215761A1 (en) * 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
DE60313855T2 (de) * 2002-03-28 2007-09-20 The Genetics Co. Inc. Wachstums-regulierende gene
US7416730B2 (en) * 2002-04-18 2008-08-26 Yeda Research And Development Co. Ltd. Derivatives of the IL-2 receptor gamma chain, their production and use
JP4344928B2 (ja) * 2002-04-24 2009-10-14 萬有製薬株式会社 ヒスタミン受容体ｈ３常活性変異体およびその利用
US20030055221A1 (en) * 2002-05-07 2003-03-20 Jirong Lu Stability of flint through o-linked glycosylation
EP1382613A1 (de) * 2002-07-16 2004-01-21 Sumitomo Chemical Company, Limited Neues G Protein, kodierende Nukleotidsequenzen und Verwendung des Proteins
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
CN1777443B (zh) * 2002-07-19 2010-06-23 貝丝以色列女执事医疗中心 诊断和治疗先兆子痫或子痫的方法
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
GB0219303D0 (en) * 2002-08-19 2002-09-25 Ares Trading Sa Protein
JP2006515177A (ja) * 2002-09-10 2006-05-25 ロランティス リミテッド Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置
WO2004032837A2 (en) * 2002-10-08 2004-04-22 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
GB0223984D0 (en) * 2002-10-15 2002-11-20 Novartis Forschungsstiftung Methods for detecting teneurin signalling and related screening methods
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040235747A1 (en) * 2003-01-02 2004-11-25 Ramot At Tel-Aviv University Ltd. Methods of treating and/or preventing autoimmune diseases
US20060276385A1 (en) * 2003-01-13 2006-12-07 Hanjoong Jo Anti-inflammatory agents and methods of their use
EP1590462A2 (de) * 2003-02-05 2005-11-02 Applied Research Systems ARS Holding N.V. Mucinähnliche polypeptide
US7736646B2 (en) * 2003-03-12 2010-06-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US7084246B2 (en) * 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
ATE433759T1 (de) 2003-04-18 2009-07-15 Biogen Idec Inc Polymerkonjugiertes glycosiliertes neublastin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
WO2005110009A2 (en) * 2003-07-22 2005-11-24 Immunex Corporation COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
KR100632985B1 (ko) * 2003-07-26 2006-10-11 메덱스젠 주식회사 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
ES2388138T3 (es) * 2003-08-27 2012-10-09 Ophthotech Corporation Terapia de combinación para tratamiento de trastornos neovasculares oculares
ATE390144T1 (de) * 2003-09-08 2008-04-15 Serono Lab Behandlung von fibrosen
EP2261331A1 (de) * 2003-09-11 2010-12-15 Hubit Genomix, Inc. Verfahren und Kit zur Detektion proliferativer, Sklerose verursachender Erkrankungen, Vorbeugungsmittel und/oder Heilmittel für proliferative, Sklerose verursachende Erkrankungen und Verfahren und Kit zur Identifizierung einer wirksamen Substanz zur Vorbeugung und/oder Behandlung proliferativer, Sklerose verursachender Erkrankungen
EA010650B1 (ru) * 2003-09-29 2008-10-30 Уоррен Фармасьютикалз, Инк. Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
WO2005040194A2 (en) * 2003-10-24 2005-05-06 Ludwig Institute For Cancer Research Methods and compositions for pdgf-c activation and inhibition
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005051994A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Ztnf11, a tumor necrosis factor
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US20050255496A1 (en) * 2003-12-16 2005-11-17 Zeren Gao Ztnf12, a tumor necrosis factor
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
US20050176073A1 (en) * 2004-02-06 2005-08-11 Chemocentryx, Inc. Cell proliferation associated with CCX CKR expression
EP1773349A4 (de) * 2004-05-04 2009-07-29 Childrens Medical Center Verfahren und zusammensetzungen zur behandlung von präeklampsie
EP1612892B1 (de) * 2004-06-30 2008-03-19 Tyco Electronics Nederland B.V. Verbinder für elektronische Bauteile
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
AR050608A1 (es) * 2004-08-19 2006-11-08 Alza Corp Aparato y metodo para administracion transdermica de factores de crecimiento endotelial vascular
CA2577755C (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Neublastin variants
JP4959566B2 (ja) * 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US20060090646A1 (en) * 2004-11-04 2006-05-04 Questair Technologies Inc. Adsorbent material for selective adsorption of carbon monoxide and unsaturated hydrocarbons
ES2523457T3 (es) 2004-11-18 2014-11-26 Imclone Llc Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
AU2005337873A1 (en) * 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
SG173313A1 (en) 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
WO2006094106A2 (en) 2005-02-28 2006-09-08 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
CA2601086A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
JP2008547006A (ja) * 2005-06-17 2008-12-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 変形性関節症のタンパク質プロフィール
JP2008546707A (ja) * 2005-06-17 2008-12-25 ジェネンテック・インコーポレーテッド 創傷治癒
US8329175B2 (en) * 2005-08-26 2012-12-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
US20080032343A1 (en) 2005-12-22 2008-02-07 Genentech, Inc. Recombinant Production of Heparin Binding Proteins
US7659250B2 (en) * 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
US9878003B2 (en) 2006-03-06 2018-01-30 The University Of Manchester Method of treating bone disorders using TSG-6
GB0604460D0 (en) * 2006-03-06 2006-04-12 Isis Innovation Treatment
US8101564B2 (en) * 2006-05-03 2012-01-24 Trustees Of The University Of Pennsylvania Methods for regulating osteoclast differentiation and bone resorption using LRRc17
ES2429225T3 (es) 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
ES2532848T3 (es) * 2006-07-04 2015-04-01 Combigene Ab Uso de secuencias de ácidos nucleicos para el tratamiento de enfermedades neurológicas y psiquiátricas, vectores y composiciones
AU2007272412B2 (en) 2006-07-14 2013-11-07 Genentech, Inc. Refolding of recombinant proteins
JP2010507567A (ja) * 2006-08-07 2010-03-11 ジェンザイム・コーポレーション 併用療法
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US8865169B2 (en) * 2007-02-20 2014-10-21 Tufts University Methods and systems for multi-antibody therapies
KR100984483B1 (ko) * 2007-03-19 2010-10-01 (주)바이오니아 순환적 역전사 방법
US20080234194A1 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
WO2008116116A2 (en) * 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US8329655B2 (en) * 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
EP2205634A2 (de) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin-antikörper und anwendungen davon
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
AU2009233718A1 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
US20120190042A1 (en) * 2009-01-22 2012-07-26 Reuben Gobezie Protein biomarkers and therapeutic targets for osteoarthritis
KR20170134788A (ko) 2009-03-30 2017-12-06 악셀레론 파마 인코포레이티드 Ｂｍｐ-ａｌｋ3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도
US20100279882A1 (en) * 2009-05-01 2010-11-04 Mostafa Ronaghi Sequencing methods
MX2012000214A (es) * 2009-06-23 2012-01-25 Univ California Aumento de retencion de bmp.
US9409983B2 (en) * 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
EP2536432B1 (de) * 2010-02-19 2018-08-08 Cornell University Verfahren zur behandlung demyelinisierender autoimmunerkrankungen und anderer autoimmun- oder entzündungserkrankungen
US8853164B2 (en) * 2010-02-26 2014-10-07 Osstemimplant Co., Ltd. Oligopeptide improving differentiation of osteoblasts
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
EP2706041B1 (de) 2010-05-14 2018-10-03 Beth Israel Deaconess Medical Center Extrakorporale Vorrichtungen und Verfahren zur Behandlung von Komplikationen während der Schwangerschaft
JP2013530187A (ja) * 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患を治療するための組成物及び方法。
MX2013000301A (es) 2010-07-09 2013-05-09 Biogen Idec Hemophilia Inc Factores quimericos de coagulacion.
WO2012092566A1 (en) * 2010-12-30 2012-07-05 Surmodics, Inc. Cell attachment coatings and methods
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US8507446B2 (en) * 2011-08-09 2013-08-13 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating liver cirrhosis
KR102104686B1 (ko) 2012-01-10 2020-04-24 바이오젠 엠에이 인코포레이티드 뇌혈관 장벽을 통한 치료학적 분자의 수송 개선법
US9920295B2 (en) * 2012-02-21 2018-03-20 The Trustees Of The University Of Pennsylvania Bioreactor for isolation of rare cells and methods of use
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9133440B2 (en) * 2012-09-27 2015-09-15 Claresa Levetan Generation of new pancreatic beta cells
EP2950807B1 (de) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Zusammensetzungen und verfahren zur verwendung bei der behandlung von stoffwechselerkrankungen
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
CN105431204A (zh) 2013-07-12 2016-03-23 奥普索特克公司 用于治疗或预防眼科病的方法
CA2933552A1 (en) * 2013-12-23 2015-07-02 Alk-Abello A/S Peptide combinations and uses thereof in treating dust mite allergy
KR20170065026A (ko) * 2014-07-30 2017-06-12 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애 치료용으로 이용되는 조성물 및 방법
CA2961587A1 (en) 2014-10-31 2016-05-06 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
ES2893114T3 (es) 2015-02-04 2022-02-08 Bristol Myers Squibb Co Métodos para seleccionar moléculas terapéuticas
RU2017127609A (ru) 2015-02-04 2019-03-04 Ф. Хоффманн-Ля Рош Аг Антисмысловые олигомеры тау-белка и их применение
EP3277815B1 (de) 2015-04-03 2021-09-22 University of Massachusetts Oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen
CA3011894A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
JP2021533762A (ja) 2018-08-10 2021-12-09 ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts Ｓｎｐを標的化する修飾オリゴヌクレオチド
EP4359539A1 (de) 2021-06-23 2024-05-01 University Of Massachusetts Optimierte anti-flt1-oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61272063A (ja) * 1985-05-29 1986-12-02 東レ株式会社 マスク
JPH0638860B2 (ja) * 1986-06-30 1994-05-25 日本バイリ−ン株式会社 成形マスク
DE3735787A1 (de) * 1987-09-22 1989-03-30 Stiftung Inst Fuer Werkstoffte Verfahren und vorrichtung zum zerstaeuben mindestens eines strahls eines fluessigen stoffs, vorzugsweise geschmolzenen metalls
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
DK0464155T3 (da) * 1989-03-24 1997-11-17 Univ California Endotelcellevækstfaktor, isolering og ekspression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
JPH06339542A (ja) * 1994-04-20 1994-12-13 Asahi Chem Ind Co Ltd 防塵マスク
JPH08107939A (ja) * 1994-10-11 1996-04-30 Takehiko Tatsumi マスク
JP4251677B2 (ja) * 1997-10-13 2009-04-08 大和紡績株式会社 使い捨てマスク
JP3578631B2 (ja) * 1998-06-16 2004-10-20 サンエム・パッケージ株式会社 マスク

Also Published As

Publication number Publication date
AU6079890A (en) 1991-03-11
EP0484401B1 (de) 1996-09-11
JP3523645B2 (ja) 2004-04-26
US5194596A (en) 1993-03-16
ES2094159T3 (es) 1997-01-16
JP2007068545A (ja) 2007-03-22
WO1991002058A1 (en) 1991-02-21
EP0484401A4 (en) 1992-08-19
CA2063810A1 (en) 1991-01-28
DK0484401T3 (da) 1996-09-30
JPH05501350A (ja) 1993-03-18
JPH10309191A (ja) 1998-11-24
ATE142693T1 (de) 1996-09-15
CA2063810C (en) 2003-02-04
DE69028535T2 (de) 1997-04-10
JP2004000255A (ja) 2004-01-08
EP0484401A1 (de) 1992-05-13

Similar Documents

Publication Publication Date Title
DE69028535D1 (de) Herstellung des vaskulären endothelialen zellwachstumsfaktors
ATE234921T1 (de) Osteoinduktive zusammensetzungen
ATE209251T1 (de) Knochen- und knorpel-bildung hervorrufende proteine
DE693928T1 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
DE68923819T2 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ES2127757T3 (es) Composiciones bmp-9.
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
ES8600613A1 (es) Procedimiento para el tratamiento de tejidos corporales
DK0429570T3 (da) Osteoinducerende præparater
DE69132918D1 (de) Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
DK0691849T3 (da) Osteoblastvækststimulerende præparat indeholdende PDGF og vitamin D
ATE106754T1 (de) Verfahren zur herstellung von rinder-pericard- materialien und ihre verwendung.
DE69133338D1 (de) Bmp-5-derivate
RU93037867A (ru) Способ лечения длительно незаживающих ран и трофических язв кожных покровов
NZ333652A (en) Inhibition of human rotavirus infection using kappa-casein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition